-46%

est. 2Y upside i

HealthcareSeries D+

Rank

#3264

Sector

Neurotechnology / Medical Devices

Est. Liquidity

~4Y

Data Quality

Data: High

Synchron operates in the high-potential neurotechnology sector with a strong competitive moat via its minimally invasive Stentrode BCI and positive early clinical trial results.

Last updated: March 10, 2026

Bull (15%)+175%

Synchron successfully navigates pivotal trials and achieves commercial launch of its Stentrode BCI, gaining significant market share due to its minimally invasive approach and strong partnerships with tech giants like Apple and Nvidia. Revenue scales to over $300M by 2028, justifying a $2.75B+ valuation at 9x revenue, well above the current $1.0B.

Base (45%)+40%

Synchron continues to make progress in clinical trials and secures initial commercialization, capturing a meaningful segment of the BCI market despite ongoing competition from Neuralink and other players. Growth is steady, reaching ~$150M revenue by 2028 and a $1.4B valuation at IPO or acquisition, offering a moderate return.

Bear (40%)-60%

Pivotal trials face significant delays or unexpected challenges, or Neuralink/medical device incumbents gain a decisive lead in technology or market adoption. Regulatory hurdles prove more difficult, limiting market access. High capital intensity necessitates further dilutive funding rounds at a flat or lower valuation, wiping out most common-stock value given the severe liquidation preferences, resulting in a valuation of $400M or less.

Est. time to liquidity~3.5 years

Preference Stack Risk

severe

Funding Intensity

35%

Investors have put in $345M. In an exit at or below the current $1.0B valuation, common stock holders would be behind $345M in liquidation preferences.

Dilution Risk

high

As a clinical-stage company preparing for pivotal trials and commercial launch, Synchron will likely need significant additional funding rounds before an IPO or acquisition, leading to further dilution.

Secondary Liquidity

limited

Some platforms like UpMarket facilitate pre-IPO share transactions, indicating limited secondary market activity, but it's not broadly active for employees.

Other — 5 roles

View all 5 open roles at Synchron →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Synchron's data — designed to show you've done your homework.

  • 1

    “How does Synchron plan to maintain its competitive advantage with the minimally invasive Stentrode, especially as Neuralink and other competitors advance their own BCI technologies and potentially improve their surgical approaches?”

  • 2

    “Given the high capital intensity and regulatory hurdles, what are the key milestones and financial projections for achieving profitability and scaling device sales and subscription revenue over the next 3-5 years?”

  • 3

    “With a Series D funding round completed, what is the company's anticipated timeline and strategy for a liquidity event (IPO or acquisition), and how does the preference stack impact potential returns for common stock holders?”

Community

Valuation Sentiment

Our model estimates -46% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.